![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
WB Parker, AR Bapat, JX Shen, AJ Townsend and YC Cheng
Department of Pharmacology, University of North Carolina, School of Medicine, Chapel Hill 27599.
Recently, 2-halogenated deoxyadenosine analogs (F, Cl, and Br) have been shown to have antitumor activity. These analogs are phosphorylated by cells and are believed to exert their cytotoxic action at the nucleoside triphosphate level. In this work the interaction of these nucleoside triphosphate analogs with potential targets, such as DNA polymerase alpha, beta, and gamma, DNA primase, and ribonucleotide reductase was examined in detail. All of these compounds competitively inhibited the incorporation of dAMP into DNA by DNA polymerase alpha, beta, or gamma. F-dATP was able to completely substitute for dATP using DNA polymerase alpha and gamma, but not with DNA polymerase beta. Cl- dATP and Br-dATP substituted poorly for dATP using DNA polymerase alpha and beta. Extension of a 32P-labeled primer by DNA polymerase alpha, beta, or gamma on a single-stranded M13 template showed that these compounds were incorporated into the 3' end of the growing DNA chain and that elongation beyond the incorporated analogs was significantly retarded for Cl-dATP and Br-dATP using either DNA polymerase alpha or beta. DNA primase using poly(dC) as template was inhibited by these compounds at a concentration 4 to 5 times greater than that required for 2-F-araATP. The 2-halogenated dATP analogs were potent inhibitors of ADP reduction by ribonucleotide reductase. In conclusion, the cytotoxic action of 2-Cl-deoxyadenosine and 2-Br-deoxyadenosine may partially be mediated through the mechanism of "self-potentiation," by depression of the deoxynucleoside triphosphate pools due to inhibition of ribonucleotide reductase, which would facilitate their incorporation into DNA and result in the inhibition of DNA synthesis.
This article has been cited by other articles:
|
|
 |
|
  V. Gandhi, W. Plunkett, P. L. Bonate, M. Du, B. Nowak, S. Lerner, and M. J. Keating Clinical and Pharmacokinetic Study of Clofarabine in Chronic Lymphocytic Leukemia: Strategy for Treatment. Clin. Cancer Res., July 1, 2006; 12(13): 4011 - 4017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Faderl, S. Verstovsek, J. Cortes, F. Ravandi, M. Beran, G. Garcia-Manero, A. Ferrajoli, Z. Estrov, S. O'Brien, C. Koller, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older Blood, July 1, 2006; 108(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Faderl, V. Gandhi, S. O'Brien, P. Bonate, J. Cortes, E. Estey, M. Beran, W. Wierda, G. Garcia-Manero, A. Ferrajoli, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias Blood, February 1, 2005; 105(3): 940 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Gandhi, H. Kantarjian, S. Faderl, P. Bonate, M. Du, M. Ayres, M. B. Rios, M. J. Keating, and W. Plunkett Pharmacokinetics and Pharmacodynamics of Plasma Clofarabine and Cellular Clofarabine Triphosphate in Patients with Acute Leukemias Clin. Cancer Res., December 15, 2003; 9(17): 6335 - 6342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kantarjian, V. Gandhi, J. Cortes, S. Verstovsek, M. Du, G. Garcia-Manero, F. Giles, S. Faderl, S. O'Brien, S. Jeha, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia Blood, October 1, 2003; 102(7): 2379 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. McLaughlin Progress and Promise in the Treatment of Indolent Lymphomas Oncologist, June 1, 2002; 7(3): 217 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Gandhi, W. Plunkett, M. Du, M. Ayres, and E. H. Estey Prolonged Infusion of Gemcitabine: Clinical and Pharmacodynamic Studies During a Phase I Trial in Relapsed Acute Myelogenous Leukemia J. Clin. Oncol., February 1, 2002; 20(3): 665 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ahmad, A. M. Al-Katib, F. W. J. Beck, and R. M. Mohammad Sequential Treatment of a Resistant Chronic Lymphocytic Leukemia Patient with Bryostatin 1 Followed by 2-Chlorodeoxyadenosine: Case Report Clin. Cancer Res., April 1, 2000; 6(4): 1328 - 1332. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Genini, I. Budihardjo, W. Plunkett, X. Wang, C. J. Carrera, H. B. Cottam, D. A. Carson, and L. M. Leoni Nucleotide Requirements for the in Vitro Activation of the Apoptosis Protein-activating Factor-1-mediated Caspase Pathway J. Biol. Chem., January 7, 2000; 275(1): 29 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Leoni, Q. Chao, H. B. Cottam, D. Genini, M. Rosenbach, C. J. Carrera, I. Budihardjo, X. Wang, and D. A. Carson Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c PNAS, August 4, 1998; 95(16): 9567 - 9571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hentosh and M. Tibudan 2-Chloro-2'-deoxyadenosine, an Antileukemic Drug, Has an Early Effect on Cellular Mitochondrial Function Mol. Pharmacol., April 1, 1997; 51(4): 613 - 619. [Abstract] [Full Text]
|
|
|
|
|
|
K.-i. Kamiya, P. Huang, and W. Plunkett Inhibition of the 3' right-arrow 5' Exonuclease of Human DNA Polymerase epsilon by Fludarabine-terminated DNA J. Biol. Chem., August 9, 1996; 271(32): 19428 - 19435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Fidias, B. A. Chabner, and M. L. Grossbard Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders Oncologist, June 1, 1996; 1(3): 125 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Kolesar, A. K. Morris, and J. G. Kuhn Review : Purine nucleoside analogues: Fludarabine, pentostatin, and cladribine: Part 1: Fludarabine Journal of Oncology Pharmacy Practice, January 1, 1996; 2(3): 160 - 181. [Abstract] [PDF]
|
|
|
|
|
|
C. Harrington and F. W. Perrino The Effects of Cytosine Arabinoside on RNA-primed DNA Synthesis by DNA Polymerase alpha-Primase J. Biol. Chem., November 3, 1995; 270(44): 26664 - 26669. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
